Some features of this website DO NOT support IE. Please use Chrome or Edge, or other browsers.

QT Medical® Announces Completion of Series B Financing of $12 Million

QT Medical, Inc. (QT Medical), a medtech company focusing on electrocardiogram (ECG or EKG) technology, announces today that it raised $12 million in Series B financing. This funding will accelerate QT Medical’s market penetration, global expansion, product pipeline development, and long-term strategic planning.

Relocation Notice of Taipei Office

We extend our heartfelt gratitude for your continuous support. QT Medical is pleased to inform you that our Taipei office has relocated to a new address: 6th Floor, No. 9, Section 1, Zhongxiao East Road, Zhongzheng District, Taipei City 10009, Taiwan

QT Medical Wins Taipei Biotech Award 2021 !

QT Medical Wins Taipei Biotech Award 2021 !

Portable ECG Machine and EKG Machine Buyer's Guide For Professionals

How to Choose the Best ECG Machine for Your Clinical Practice

QT MEDICAL, Inc. featured in Medical Taiwan 2020

QT MEDICAL_Medical Taiwan_Medical devices & equipment

For the golden rescue time, Yuxin Biomedical donated 15 sets of "12-lead electrocardiographs" to Zhongshi

Cardiovascular disease is the second among the top ten causes of death in China. Time is the most important key to treating patients with acute myocardial infarction. In order to assist Taichung to improve emergency rescue energy, the Taiwan Branch of American Merchant Uxin Biomedical Co., Ltd. specially donated 15 sets of 12-lead ECG systems.

There Is a Better Way to Get a Standard 12-Lead ECG Test During the COVID-19 Pandemic

QT Medical launches the worlds first 12-lead ECG service for home use - Xpress ECG™

PCA 500-- the world's most efficient and versatile 12-lead ECG, just received FDA clearance for pediatric use

QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients. First cleared in 2018 for professional and personal use by adults 18 years and older, PCA 500's new FDA clearance expands its indication for use to all pediatric populations, including: newborns, infants, children and adolescents.


This website uses cookies to collect information about your browsing session so we can provide the best experience possible.